search
Back to results

Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System

Primary Purpose

Back Pain, Chronic Low Back Pain, Internal Disc Disruption

Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
BIOSTAT BIOLOGX
Saline
Sponsored by
Spinal Restoration, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Back Pain focused on measuring intervertebral disk

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 or older and skeletally mature.
  • Voluntarily signs the subject informed consent form and agrees to the release of medical information for purposes of this study (HIPAA authorization).
  • Physically and mentally able to comply with the protocol, including ability to read and complete required forms, and willing and able to adhere to the follow-up requirements of the protocol.
  • Chronic low back pain for at least 6 months.
  • Pretreatment baseline low back pain of at least 40 mm on a 100 mm visual analog scale.
  • Pretreatment baseline Roland-Morris Disability Questionnaire score of at least 9 on the 24-point questionnaire.
  • Leg pain, if present, is of nonradicular origin, i.e., not due to stimulation of nerve roots or dorsal root ganglion of a spinal nerve by compressive forces.
  • Leg pain, if present, does not extend below the knee and is no greater than 50% of low back pain as measured on a visual analog scale. If bilateral leg pain, the worst leg pain is no greater than 50% of low back pain.
  • Low back pain unresponsive to at least 3 months of nonoperative care, which may include bed rest, antiinflammatory and analgesic medications, chiropractic manipulations, acupuncture, massage, physical therapy or home-directed lumbar exercise program.
  • Diagnostic medial branch block or facet joint injection between 18 months and 2 weeks prior to the study procedure indicates no facet joint involvement.
  • Diagnosis of symptomatic lumbar (L1-L2 - L5-S1) internal disc disruption (IDD), which requires confirmation of discogenic pain at one or two contiguous levels through positive provocation discography performed between 18 months and 2 weeks prior to the study procedure using pressure manometry and identification of an adjacent nonpainful disc. The disc provocation studies must precisely demonstrate concordant pain (<50 psi above opening pressure) and must demonstrate a fissure(s) in the outer one-third of the posterior or lateral anulus.

Exclusion Criteria:

  • Cauda equina syndrome.
  • Active malignancy or tumor as source of symptoms.
  • Current infection or prior history of spinal infection (e.g., discitis, septic arthritis, epidural abscess) or an active systemic infection.
  • Previous lumbar spine surgery.
  • Evidence of prior lumbar vertebral body fracture.
  • Disc bulge/protrusion or focal herniation at the symptomatic level(s) > 4 mm.
  • Presence of disc extrusion or sequestration.
  • Leg pain is greater than 50% of low back pain as measured on a visual analog scale.
  • Leg pain that extends below the knee.
  • Lumbar intervertebral foramen stenosis at the affected level(s) resulting in significant spinal nerve root compression (effacement of the majority of periganglion fat and loss of CSF signal around the nerve rootlets).
  • Symptomatic central vertebral canal stenosis or absolute sagittal vertebral canal diameter < 9mm.
  • Loss of disc space height at the symptomatic level(s) greater than one-third of an adjacent normal disc (or of the expected height in the case of an L5-S1 disc).
  • Spondylolisthesis (> Grade 1) with or without spondylolysis at the symptomatic level(s).
  • Lumbar spondylitis or other undifferentiated spondyloarthropathy.
  • Dynamic instability at the symptomatic level(s) on lumbar flexion-extension radiographs indicated by >4.5 mm of translation or angular motion >15° at L1-L2, L2-L3, or L3-L4; >20° at L4-L5; or >25° at L5-S1.
  • Diagnostic medial branch block or facet joint injection indicate facet joint involvement.
  • Diagnostic sacroiliac injection indicates sacroiliac joint involvement for those patients with pain in the sacral region.
  • Sustained relief (>3 months) of low back pain obtained with epidural injection of corticosteroids.
  • Symptomatic involvement of more than two lumbar disc levels determined from discography.
  • Neurological examination shows findings of radiculopathy or a significant underlying neurological condition (motor strength <4; sensory assessment abnormal; or reflexes absent or hyperactive with clonus).
  • Prior thermal intradiscal procedure (e.g., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation).
  • Any lumbar intradiscal injection procedure other than discography (e.g., injection of corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate).
  • Significant systemic disease, including unstable angina, autoimmune disease, rheumatoid arthritis, and muscular dystrophy.
  • Congenital or acquired coagulopathy or thrombocytopenia; or currently taking anticoagulant, antineoplastic, antiplatelet, or thrombocytopenia-inducing medications; or undergoing radiation therapy.
  • History of unexplained, easy, or persistent bruising or bleeding, bleeding from the gums, or bleeding problems experienced in previous surgical procedures.
  • Aspirin or aspirin-containing medication taken ≤ 7 days prior to the procedure.
  • Known or suspected hypersensitivity or allergy to drugs or components of the fibrin sealant (fibrinogen, thrombin, aprotinin, CaCl2) used in the procedure.
  • History of, or current psychiatric or psychological condition, or substance or alcohol abuse that would potentially interfere with the subject's participation in the study.
  • Ongoing or previous participation in another drug or device clinical study within the previous 2 months.
  • Subject known to be pregnant or nursing at time of enrollment or with plans to become pregnant within the planned length of follow-up.
  • Body habitus precludes adequate fluoroscopic visualization for the procedure or the procedure is physically impossible using the device.
  • Concomitant conditions requiring daily oral steroid use for more than 30 days in the preceding 90 days.
  • Pending litigation against a health care professional, except where required by the insurer as a condition of coverage, personal injury compensation or litigation claims.
  • Prisoner or active military personnel who would not be available for follow-up.
  • Presence of ferromagnetic implants that would disallow MRI of the symptomatic disc(s).
  • Active or pending workers' compensation claims.

Sites / Locations

  • Alabama Clinical Therapeutics, LLC
  • HOPE Research Institute
  • Pain Control Associates of San Diego
  • Napa Pain Institute
  • California Spine Diagnostics
  • The Spine Institute
  • The Pain Institute, Inc
  • Millennium Pain Center
  • The Spine Center
  • Medical Advanced Pain Specialists Applied Research Center
  • NewSouth NeuroSpine Pain Center
  • OrthoCarolina Spine Center
  • Cleveland Clinic
  • OrthoNeuro, Inc.
  • Allegheny Pain Management
  • Orthopaedic & Spine Specialists
  • Spine Specialists PA
  • Virginia Spine Research Institute
  • Advanced Pain Management
  • Bellingham Spine Pain Specialists PS

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

BIOSTAT BIOLOGX

Saline

Arm Description

One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc

One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc

Outcomes

Primary Outcome Measures

Subject Composite Success
Subject success based on a composite of minimum 30% decrease in low back pain, 30% improvement in function, maintenance of neurological status, no secondary interventions, and no serious adverse events.

Secondary Outcome Measures

Visual Analog Scale for Low Back Pain
Percent of subjects achieving a minimum 30% decrease in pain from baseline. The visual analog scale is a horizontal 100 mm line anchored on the left with the words "No Pain" and on the right with the words "Worst Possible Pain". Scores were obtained by measuring the distance in millimeters from the left origin of the line (0) to the point indicated with a slash placed by the subject to indicate the subject's level of low back pain experienced over the last week.
Roland-Morris Disability Questionnaire Score
Percent of subjects achieving a minimum 30% decrease in Roland-Morris Disability Questionnaire score The Roland-Morris Disability Questionnaire is a widely studied and frequently used instrument for the assessment of function and disability related to low back pain. The questionnaire consists of 24 statements related to how a subject's back condition affects various activities of daily living. Subjects marked whether the statement either applied to them or did not apply at the time they responded to the statements. The score is the total number of questions with which the subject agreed. A higher score indicates less function and greater disability.

Full Information

First Posted
November 9, 2009
Last Updated
May 5, 2014
Sponsor
Spinal Restoration, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01011816
Brief Title
Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System
Official Title
A Multicenter, Randomized, Blinded, Saline-Controlled Trial of Resorbable Biologic Disc Augmentation for Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Terminated
Why Stopped
Stopped prior to last subject's last extended follow-up visit (78 weeks) due to lack of efficacy at the primary study endpoint (26 weeks)
Study Start Date
March 2010 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
May 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Spinal Restoration, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this investigation is to establish the safety and efficacy of the Biostat System when used for treatment of chronic low back (lumbar) pain due to symptomatic internal disc disruptions (IDD) by comparing safety and efficacy outcome measures between one group receiving BIOSTAT BIOLOGX® Fibrin Sealant through the Biostat® Delivery Device and another group receiving a preservative-free normal saline control delivered with the Biostat Delivery Device.
Detailed Description
The Biostat System is a combination product combining a resorbable biologic product with a delivery device system used to prepare and insert the biologic material into a lumbar intervertebral disc. Symptomatic IDD is defined as a painful disruption of the internal architecture of a lumbar intervertebral disc, which appears as fissures, cracks or tears within the internal structures of the disc. Pain arising from a lumbar disc may not only be perceived as pain located in the low back (axial pain) but also as somatic referred pain involving the posterior hips, buttocks, lateral hips, groin, or posterior thighs. The diagnosis of symptomatic IDD cannot currently be made on the basis of imaging studies, physical examination, or symptoms alone, and is best established with meticulously conducted disc provocation studies (provocation discography) that include pressure manometry and identification of an adjacent normal disc. This treatment and study are not designed for patients exhibiting other potential sources of chronic low back pain such as more advanced degenerative disc disease with significant loss of disc height (>33%), spinal stenosis, or spondylolisthesis (see Eligibility Criteria).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Back Pain, Chronic Low Back Pain, Internal Disc Disruption, Degenerative Disc Disease
Keywords
intervertebral disk

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
220 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BIOSTAT BIOLOGX
Arm Type
Experimental
Arm Description
One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc
Arm Title
Saline
Arm Type
Placebo Comparator
Arm Description
One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc
Intervention Type
Biological
Intervention Name(s)
BIOSTAT BIOLOGX
Other Intervention Name(s)
Fibrin Sealant
Intervention Description
One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
Intervention Type
Drug
Intervention Name(s)
Saline
Other Intervention Name(s)
0.9% w/v Sodium Chloride Injection, USP
Intervention Description
One injection of up to 4 mL of saline using the Biostat Delivery Device
Primary Outcome Measure Information:
Title
Subject Composite Success
Description
Subject success based on a composite of minimum 30% decrease in low back pain, 30% improvement in function, maintenance of neurological status, no secondary interventions, and no serious adverse events.
Time Frame
26 weeks
Secondary Outcome Measure Information:
Title
Visual Analog Scale for Low Back Pain
Description
Percent of subjects achieving a minimum 30% decrease in pain from baseline. The visual analog scale is a horizontal 100 mm line anchored on the left with the words "No Pain" and on the right with the words "Worst Possible Pain". Scores were obtained by measuring the distance in millimeters from the left origin of the line (0) to the point indicated with a slash placed by the subject to indicate the subject's level of low back pain experienced over the last week.
Time Frame
26-weeks
Title
Roland-Morris Disability Questionnaire Score
Description
Percent of subjects achieving a minimum 30% decrease in Roland-Morris Disability Questionnaire score The Roland-Morris Disability Questionnaire is a widely studied and frequently used instrument for the assessment of function and disability related to low back pain. The questionnaire consists of 24 statements related to how a subject's back condition affects various activities of daily living. Subjects marked whether the statement either applied to them or did not apply at the time they responded to the statements. The score is the total number of questions with which the subject agreed. A higher score indicates less function and greater disability.
Time Frame
26-weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 or older and skeletally mature. Voluntarily signs the subject informed consent form and agrees to the release of medical information for purposes of this study (HIPAA authorization). Physically and mentally able to comply with the protocol, including ability to read and complete required forms, and willing and able to adhere to the follow-up requirements of the protocol. Chronic low back pain for at least 6 months. Pretreatment baseline low back pain of at least 40 mm on a 100 mm visual analog scale. Pretreatment baseline Roland-Morris Disability Questionnaire score of at least 9 on the 24-point questionnaire. Leg pain, if present, is of nonradicular origin, i.e., not due to stimulation of nerve roots or dorsal root ganglion of a spinal nerve by compressive forces. Leg pain, if present, does not extend below the knee and is no greater than 50% of low back pain as measured on a visual analog scale. If bilateral leg pain, the worst leg pain is no greater than 50% of low back pain. Low back pain unresponsive to at least 3 months of nonoperative care, which may include bed rest, antiinflammatory and analgesic medications, chiropractic manipulations, acupuncture, massage, physical therapy or home-directed lumbar exercise program. Diagnostic medial branch block or facet joint injection between 18 months and 2 weeks prior to the study procedure indicates no facet joint involvement. Diagnosis of symptomatic lumbar (L1-L2 - L5-S1) internal disc disruption (IDD), which requires confirmation of discogenic pain at one or two contiguous levels through positive provocation discography performed between 18 months and 2 weeks prior to the study procedure using pressure manometry and identification of an adjacent nonpainful disc. The disc provocation studies must precisely demonstrate concordant pain (<50 psi above opening pressure) and must demonstrate a fissure(s) in the outer one-third of the posterior or lateral anulus. Exclusion Criteria: Cauda equina syndrome. Active malignancy or tumor as source of symptoms. Current infection or prior history of spinal infection (e.g., discitis, septic arthritis, epidural abscess) or an active systemic infection. Previous lumbar spine surgery. Evidence of prior lumbar vertebral body fracture. Disc bulge/protrusion or focal herniation at the symptomatic level(s) > 4 mm. Presence of disc extrusion or sequestration. Leg pain is greater than 50% of low back pain as measured on a visual analog scale. Leg pain that extends below the knee. Lumbar intervertebral foramen stenosis at the affected level(s) resulting in significant spinal nerve root compression (effacement of the majority of periganglion fat and loss of CSF signal around the nerve rootlets). Symptomatic central vertebral canal stenosis or absolute sagittal vertebral canal diameter < 9mm. Loss of disc space height at the symptomatic level(s) greater than one-third of an adjacent normal disc (or of the expected height in the case of an L5-S1 disc). Spondylolisthesis (> Grade 1) with or without spondylolysis at the symptomatic level(s). Lumbar spondylitis or other undifferentiated spondyloarthropathy. Dynamic instability at the symptomatic level(s) on lumbar flexion-extension radiographs indicated by >4.5 mm of translation or angular motion >15° at L1-L2, L2-L3, or L3-L4; >20° at L4-L5; or >25° at L5-S1. Diagnostic medial branch block or facet joint injection indicate facet joint involvement. Diagnostic sacroiliac injection indicates sacroiliac joint involvement for those patients with pain in the sacral region. Sustained relief (>3 months) of low back pain obtained with epidural injection of corticosteroids. Symptomatic involvement of more than two lumbar disc levels determined from discography. Neurological examination shows findings of radiculopathy or a significant underlying neurological condition (motor strength <4; sensory assessment abnormal; or reflexes absent or hyperactive with clonus). Prior thermal intradiscal procedure (e.g., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation). Any lumbar intradiscal injection procedure other than discography (e.g., injection of corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate). Significant systemic disease, including unstable angina, autoimmune disease, rheumatoid arthritis, and muscular dystrophy. Congenital or acquired coagulopathy or thrombocytopenia; or currently taking anticoagulant, antineoplastic, antiplatelet, or thrombocytopenia-inducing medications; or undergoing radiation therapy. History of unexplained, easy, or persistent bruising or bleeding, bleeding from the gums, or bleeding problems experienced in previous surgical procedures. Aspirin or aspirin-containing medication taken ≤ 7 days prior to the procedure. Known or suspected hypersensitivity or allergy to drugs or components of the fibrin sealant (fibrinogen, thrombin, aprotinin, CaCl2) used in the procedure. History of, or current psychiatric or psychological condition, or substance or alcohol abuse that would potentially interfere with the subject's participation in the study. Ongoing or previous participation in another drug or device clinical study within the previous 2 months. Subject known to be pregnant or nursing at time of enrollment or with plans to become pregnant within the planned length of follow-up. Body habitus precludes adequate fluoroscopic visualization for the procedure or the procedure is physically impossible using the device. Concomitant conditions requiring daily oral steroid use for more than 30 days in the preceding 90 days. Pending litigation against a health care professional, except where required by the insurer as a condition of coverage, personal injury compensation or litigation claims. Prisoner or active military personnel who would not be available for follow-up. Presence of ferromagnetic implants that would disallow MRI of the symptomatic disc(s). Active or pending workers' compensation claims.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin J Pauza, MD
Organizational Affiliation
Spine Specialists PA
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alabama Clinical Therapeutics, LLC
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35235
Country
United States
Facility Name
HOPE Research Institute
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85050
Country
United States
Facility Name
Pain Control Associates of San Diego
City
Chula Vista
State/Province
California
ZIP/Postal Code
91914
Country
United States
Facility Name
Napa Pain Institute
City
Napa
State/Province
California
ZIP/Postal Code
94559
Country
United States
Facility Name
California Spine Diagnostics
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Facility Name
The Spine Institute
City
Santa Monica
State/Province
California
ZIP/Postal Code
90403
Country
United States
Facility Name
The Pain Institute, Inc
City
Merritt Island
State/Province
Florida
ZIP/Postal Code
32953
Country
United States
Facility Name
Millennium Pain Center
City
Bloomington
State/Province
Illinois
ZIP/Postal Code
61701
Country
United States
Facility Name
The Spine Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21211
Country
United States
Facility Name
Medical Advanced Pain Specialists Applied Research Center
City
Edina
State/Province
Minnesota
ZIP/Postal Code
55435
Country
United States
Facility Name
NewSouth NeuroSpine Pain Center
City
Flowood
State/Province
Mississippi
ZIP/Postal Code
39232
Country
United States
Facility Name
OrthoCarolina Spine Center
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28207
Country
United States
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
OrthoNeuro, Inc.
City
New Albany
State/Province
Ohio
ZIP/Postal Code
43054
Country
United States
Facility Name
Allegheny Pain Management
City
Altoona
State/Province
Pennsylvania
ZIP/Postal Code
16602
Country
United States
Facility Name
Orthopaedic & Spine Specialists
City
York
State/Province
Pennsylvania
ZIP/Postal Code
17402
Country
United States
Facility Name
Spine Specialists PA
City
Tyler
State/Province
Texas
ZIP/Postal Code
75701
Country
United States
Facility Name
Virginia Spine Research Institute
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23235
Country
United States
Facility Name
Advanced Pain Management
City
Virginia Beach
State/Province
Virginia
ZIP/Postal Code
23454
Country
United States
Facility Name
Bellingham Spine Pain Specialists PS
City
Bellingham
State/Province
Washington
ZIP/Postal Code
98226
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
24152079
Citation
Yin W, Pauza K, Olan WJ, Doerzbacher JF, Thorne KJ. Intradiscal injection of fibrin sealant for the treatment of symptomatic lumbar internal disc disruption: results of a prospective multicenter pilot study with 24-month follow-up. Pain Med. 2014 Jan;15(1):16-31. doi: 10.1111/pme.12249. Epub 2013 Oct 23.
Results Reference
background
Citation
Buser Z, Keulling F, Jane L, Liebenberg E, Tang J, Thorne K, Coughlin D, Lotz J. Fibrin injection stimulates early disc healing in the porcine model [NASS Abstract 199]. Spine Journal 9:105S, 2009.
Results Reference
background
PubMed Identifier
21325992
Citation
Buser Z, Kuelling F, Liu J, Liebenberg E, Thorne KJ, Coughlin D, Lotz JC. Biological and biomechanical effects of fibrin injection into porcine intervertebral discs. Spine (Phila Pa 1976). 2011 Aug 15;36(18):E1201-9. doi: 10.1097/BRS.0b013e31820566b2.
Results Reference
background
Citation
Pauza K, Yin W, Olan W, Doerzbacher JF. BIOSTAT BIOLOGX(R) intradiscal fibrin sealant used for treatment of chronic low back pain caused by lumbar disc disruption: results of a 12 month, prospective multicenter pilot study. Spine Arthroplasty Society Meeting, April 27-30, 2010; New Orleans, LA. Abstract 248.
Results Reference
background
Citation
Yin W, Pauza K, Olan W, Doerzbacher JF. Long-term outcomes from a prospective, multicenter investigational device exemption (IDE) pilot study of intradiscal fibrin sealant for the treatment of discogenic pain [ISIS Abstract]. Pain Medicine 12:1446-1447, 2011
Results Reference
background
PubMed Identifier
22610998
Citation
Buser Z, Liu J, Thorne KJ, Coughlin D, Lotz JC. Inflammatory response of intervertebral disc cells is reduced by fibrin sealant scaffold in vitro. J Tissue Eng Regen Med. 2014 Jan;8(1):77-84. doi: 10.1002/term.1503. Epub 2012 May 18.
Results Reference
background

Learn more about this trial

Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System

We'll reach out to this number within 24 hrs